Investing.com - Jefferies has raised its price target on Divi’s Laboratories Ltd (NS:DIVI) to INR7,850 from INR7,150 while maintaining a Buy rating following the company’s September quarter results.

Divi’s reported a 7/18% beat on Ebitda driven by sustained revenues as well as higher gross contribution. We adjust our FY21 revenues upwards but believe that further gains from the earlier capex ...

Motilal Oswal Financial Services raised the target price for Divi's Laboratories to Rs 3,900 after the company delivered a strong beat on earnings in 4QFY24, fueled by a revival in the Custom ...

The fund invests at least 80% of its assets in the component securities of the index and in depositary receipts representing such securities. The index is based on the Morningstar® Developed Markets ...

Divi's Labs (DIVI) has delivered a 9.29% change over the past year, with a 52-week range between 5,636.50 and 7,071.50. What Is the Average Daily Trading Volume of Divi's Labs (DIVI)? The average ...

Divi’s Laboratories on Friday reported a consolidated net profit attributable to the shareholders of the company at Rs 689 crore for the second quarter ended September 2025, a 35% year-on-year (YoY) ...

MUMBAI: Shares of Divi's Laboratories rose a little over 4% after the company announced 29.3% year-on-year rise in its consolidated net profit to Rs502.02 crore for the quarter ended March. At 12pm, ...